Aug 2026
AKAP13 regulates GLI1/ULK1 axis and drive tumor resistance to next-generation HER2-targeted therapies.
It is reported that primary HER2-specific targeted therapy (tucatinib) resistant or sensitive breast cancers derived from clinical trial patients exhibited differential protein profiles and was proposed as a promising therapeutic strategy for HER2-positive breast cancer.
Qing Guo, Xinyu Chen, Linfeng Wu et al.
· Oncogene · 0 citations